Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724055 | 1.00 | MAPT (0.49) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL15308687 | 0.89 | MEN1 (0.43) | MAPTALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL4221 | 0.85 | — | — | |
| SCHEMBL237380 | 0.85 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL2375356 | 0.85 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL8891623 | 0.85 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL26115526 | 0.84 | MAPT (0.50) | MAPTALDH1A1KMT2AMEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28788727 | 0.83 | — | — | |
| SCHEMBL13044831 | 0.83 | MAPT (0.47) | MAPTALDH1A1KMT2AMEN1PPM1B | |
| SCHEMBL7894571 | 0.83 | MAPT (0.47) | MAPTALDH1A1KMT2AMEN1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-07-01 | — | — | US | disclosed |
| WO-2024114658-A1 | SUBSTITUTED 1-PHENYL-3, 4-DIHYDROPYRIDO [3, 4-D] PYRIMIDIN-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-112236424-B | Alkoxy-substituted pyridinyl derivatives | 爱杜西亚药品有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-114181077-B | Method for synthesizing tranexamic acid | 风火轮(上海)生物科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGNERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| CN-114181077-A | Method for synthesizing tranexamic acid | 风火轮(上海)生物科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-12 | — | — | US | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-8513238-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513238-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2601950-A1 | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012154519-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2011141396-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-11-10 | — | — | US | disclosed |
| US-6337034-B1 | COMPOUNDS HAVING WIDE TEMPERATURE RANGE OF LIQUID CRYSTAL PHASE, LOW VISCOSITY, LOW THRESHOLD VOLTAGE AND EXCELLENT STABILITY, WHICH ARE READILY MIXED WITH VARIOUS LIQUID CRYSTAL MATERIALS AND GOOD IN SOLUBILITY AT LOW TEMPERATURE | CHISSO CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6171664-B1 | TOLAN DERIVATIVES ARE USEFUL AS ELECTRO-OPTICAL DISPLAY; CHEMICAL, HEAT AND RADIATION RESISTANCE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2001-01-09 | — | — | US | disclosed |
| EP-0885875-A1 | VINYLENE COMPOUNDS AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | MAPT 2636/4885ALDH1A1 1468/4885KMT2A 1644/4885 |
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | LPAR1, LPAR3, LPAR2 | MAPT 4753/4885ALDH1A1 452/4885KMT2A 2392/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | MAPT 1315/4885ALDH1A1 1000/4885KMT2A 3761/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | MAPT 864/4885ALDH1A1 1029/4885KMT2A 3748/4885 |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | LPAR1, LPAR3, LPAR2 | MAPT 4753/4885ALDH1A1 452/4885KMT2A 2392/4885 |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1A, AVPR1B, OXTR | MAPT 4631/4885ALDH1A1 564/4885KMT2A 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.